Two immunotherapy drugs plus chemo for advanced bile duct cancer
Part of Cancer clinical trials.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy for people with advanced bile duct cancer that has not been treated before. The goal is to see if this new approach can help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of advanced or metastatic intrahepatic bile duct cancer that cannot be removed with surgery.
- You must not have received any prior treatment with chemotherapy, targeted therapy, or immunotherapy for your advanced cancer.
- You must be between 18 and 75 years old.
- You must be in generally good health (able to care for yourself and up and about more than 50% of waking hours).
- Your tumor must be measurable by standard scans like CT or MRI.
- Your liver and kidney function must be within acceptable ranges on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether toripalimab (an immunotherapy) combined with lenvatinib and chemotherapy works better than standard treatment for advanced intrahepatic cholangiocarcinoma. It aims to help people live longer and/or control the cancer more effectively.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This Phase 2 trial tests whether a procedure called TACE combined with the immunotherapy drug tislelizumab can shrink advanced bile duct liver cancer and help you live longer. It is for people whose cancer cannot be removed and has progressed after at least one prior treatment.
This trial tests whether combining chemotherapy, radiation, and an immunotherapy drug (sintilimab) can help people with intrahepatic bile duct cancer that hasn't been treated before. It aims to see if this triple approach is safe and effective.
This Phase 2 trial tests a combination of lenvatinib, an immunotherapy drug (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) for advanced bile duct cancer that cannot be removed with surgery. It aims to see whether this treatment can shrink tumors and improve outcomes, especially for people who have not yet had immunotherapy.
This trial tests a combination of immunotherapy (adebrelimab) and chemotherapy drugs for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that hasn't been treated yet. It aims to see if adding a targeted therapy (lenvatinib) improves outcomes.
Hear when a new Advanced Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.